BENITIONSClinical Trial Intelligence

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

第3相 完了 NCT04760626

対象疾患Diabetes Mellitus, Type 2
第3相
スポンサーNovo Nordisk A/S
ステータス完了
参加者数1,085 名
介入(薬剤)Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec, Insulin Glargine 300U/mL
開始日2021年3月1日
完了日2022年8月12日
結果公開日2025年8月26日

概要

This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App. The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will b

Change in Glycated Haemoglobin (HbA1c)

Baseline (week 0), week 52 · Percentage of HbA1c

Insulin Icodec-1.68 ± 0.09 Percentage of HbA1c
Once Daily Basal Insulin Analogue-1.31 ± 0.12 Percentage of HbA1c
p-value<0.0001
Treatment difference-0.38 (95% CI -0.66–-0.09)

BENITIONS で見る ClinicalTrials.gov の原文を見る

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。